Related Experiment Video

Updated: May 10, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Network quantification of EGFR signaling unveils potential for targeted combination therapy

Bertram Klinger1, Anja Sieber, Raphaela Fritsche-Guenther

  • 1Laboratory of Molecular Tumour Pathology, Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Molecular Systems Biology
|June 12, 2013
PubMed

Insights

Mathematical models predict that combining MEK and EGFR inhibitors can effectively treat colorectal cancer by blocking key signaling pathways. This combination therapy shows promise for both BRAF and KRAS-mutated tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Systems Biology

Background:

  • Epidermal growth factor receptor (EGFR) signaling is crucial in many solid tumors.
  • Targeted cancer therapies often require specific drug combinations for efficacy.
  • Predicting effective combinatorial treatments remains a significant challenge in oncology.

Purpose of the Study:

  • To develop a model-based approach for identifying optimal combinatorial cancer treatments.
  • To investigate the cross-talk within the RAS/PI3K signaling network in response to combined inhibitions.
  • To predict and validate novel combination therapies for colorectal cancer.

Main Methods:

  • Generated a perturbation dataset monitoring RAS/PI3K signaling in colorectal cancer cell lines.
  • Utilized mathematical modeling to analyze signaling responses to combined stimulations and inhibitions.
  • Validated predicted combination therapies in BRAF- and KRAS-mutated colorectal cancer models, including xenografts.

Main Results:

  • Identified a negative feedback loop involving EGFR that mediates cross-talk from ERK to AKT.
  • Demonstrated that MEK inhibition increases AKT activity in an EGFR-dependent manner.
  • Predicted and confirmed that combined MEK and EGFR inhibition effectively blocks both ERK and AKT signaling endpoints.
  • Showed that this combination inhibits cell growth in both BRAF- and KRAS-mutated colorectal cancer cells.

Conclusions:

  • Model-based evaluation of signaling data is a powerful tool for predicting effective cancer drug combinations.
  • Combined MEK and EGFR inhibition represents a promising therapeutic strategy for colorectal cancer, irrespective of BRAF or KRAS mutation status.
  • Understanding signaling network dynamics, including feedback loops, is essential for rational drug design in targeted cancer therapy.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...